Published in Antimicrob Agents Chemother on April 14, 2014
Drug-resistant Candida glabrata infection in cancer patients. Emerg Infect Dis (2014) 1.42
Dose escalation studies with caspofungin against Candida glabrata. J Med Microbiol (2015) 0.75
Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. Clin Infect Dis (2009) 18.19
Epidemiology of invasive candidiasis: a persistent public health problem. Clin Microbiol Rev (2007) 15.66
Echinocandin antifungal drugs. Lancet (2003) 5.92
Resistance to echinocandin-class antifungal drugs. Drug Resist Updat (2007) 4.63
Increasing echinocandin resistance in Candida glabrata: clinical failure correlates with presence of FKS mutations and elevated minimum inhibitory concentrations. Clin Infect Dis (2013) 4.14
Candida albicans and Candida glabrata clinical isolates exhibiting reduced echinocandin susceptibility. Antimicrob Agents Chemother (2006) 3.19
EUCAST technical note on the EUCAST definitive document EDef 7.2: method for the determination of broth dilution minimum inhibitory concentrations of antifungal agents for yeasts EDef 7.2 (EUCAST-AFST). Clin Microbiol Infect (2012) 2.86
Efficacy of the echinocandin caspofungin against disseminated aspergillosis and candidiasis in cyclophosphamide-induced immunosuppressed mice. Antimicrob Agents Chemother (2000) 2.51
Reduced Candida glabrata susceptibility secondary to an FKS1 mutation developed during candidemia treatment. Antimicrob Agents Chemother (2008) 2.41
Development of caspofungin resistance following prolonged therapy for invasive candidiasis secondary to Candida glabrata infection. Antimicrob Agents Chemother (2008) 2.38
Interlaboratory variability of Caspofungin MICs for Candida spp. Using CLSI and EUCAST methods: should the clinical laboratory be testing this agent? Antimicrob Agents Chemother (2013) 2.14
Low prevalence of fks1 hot spot 1 mutations in a worldwide collection of Candida strains. Antimicrob Agents Chemother (2010) 2.03
Recent exposure to caspofungin or fluconazole influences the epidemiology of candidemia: a prospective multicenter study involving 2,441 patients. Antimicrob Agents Chemother (2010) 2.02
Epidemiology and outcomes of candidemia in 3648 patients: data from the Prospective Antifungal Therapy (PATH Alliance®) registry, 2004-2008. Diagn Microbiol Infect Dis (2012) 1.88
In vivo comparison of the pharmacodynamic targets for echinocandin drugs against Candida species. Antimicrob Agents Chemother (2010) 1.88
FKS mutations and elevated echinocandin MIC values among Candida glabrata isolates from U.S. population-based surveillance. Antimicrob Agents Chemother (2010) 1.79
Candida bloodstream infections: comparison of species distribution and resistance to echinocandin and azole antifungal agents in Intensive Care Unit (ICU) and non-ICU settings in the SENTRY Antimicrobial Surveillance Program (2008-2009). Int J Antimicrob Agents (2011) 1.69
Species identification and antifungal susceptibility testing of Candida bloodstream isolates from population-based surveillance studies in two U.S. cities from 2008 to 2011. J Clin Microbiol (2012) 1.68
ESCMID* guideline for the diagnosis and management of Candida diseases 2012: adults with haematological malignancies and after haematopoietic stem cell transplantation (HCT). Clin Microbiol Infect (2012) 1.55
Comparison of dimethyl sulfoxide and water as solvents for echinocandin susceptibility testing by the EUCAST methodology. J Clin Microbiol (2012) 1.49
The presence of an FKS mutation rather than MIC is an independent risk factor for failure of echinocandin therapy among patients with invasive candidiasis due to Candida glabrata. Antimicrob Agents Chemother (2012) 1.47
Differential in vivo activities of anidulafungin, caspofungin, and micafungin against Candida glabrata isolates with and without FKS resistance mutations. Antimicrob Agents Chemother (2012) 1.44
Epidemiological changes with potential implication for antifungal prescription recommendations for fungaemia: data from a nationwide fungaemia surveillance programme. Clin Microbiol Infect (2013) 1.34
Caspofungin Etest susceptibility testing of Candida species: risk of misclassification of susceptible isolates of C. glabrata and C. krusei when adopting the revised CLSI caspofungin breakpoints. Antimicrob Agents Chemother (2012) 1.31
Frequency of fks mutations among Candida glabrata isolates from a 10-year global collection of bloodstream infection isolates. Antimicrob Agents Chemother (2013) 1.29
Fks1 and Fks2 are functionally redundant but differentially regulated in Candida glabrata: implications for echinocandin resistance. Antimicrob Agents Chemother (2012) 1.13
Global analysis of the evolution and mechanism of echinocandin resistance in Candida glabrata. PLoS Pathog (2012) 1.10
Optimizing Echinocandin dosing and susceptibility breakpoint determination via in vivo pharmacodynamic evaluation against Candida glabrata with and without fks mutations. Antimicrob Agents Chemother (2012) 1.06
EUCAST technical note on Candida and micafungin, anidulafungin and fluconazole. Mycoses (2014) 1.05
Interaction of granulocyte colony-stimulating factor and high doses of liposomal amphotericin B in the treatment of systemic murine scedosporiosis. Diagn Microbiol Infect Dis (2004) 1.04
Comparison of the fungicidal activities of caspofungin and amphotericin B against Candida glabrata. Antimicrob Agents Chemother (2005) 1.00
Comparative effects of micafungin, caspofungin, and anidulafungin against a difficult-to-treat fungal opportunistic pathogen, Candida glabrata. Antimicrob Agents Chemother (2011) 0.99
Pharmacodynamics of echinocandins against Candida glabrata: requirement for dosage escalation to achieve maximal antifungal activity in neutropenic hosts. Antimicrob Agents Chemother (2011) 0.97
Candida glabrata and FKS mutations: witnessing the emergence of the true multidrug-resistant Candida. Clin Infect Dis (2013) 0.96
Caspofungin for invasive candidiasis at a tertiary care medical center. Am J Med (2006) 0.93
Treatment of Candida glabrata infection in immunosuppressed mice by using a combination of liposomal amphotericin B with caspofungin or micafungin. Antimicrob Agents Chemother (2005) 0.92
Rapid identification of Pseudallescheria and Scedosporium strains by using rolling circle amplification. Appl Environ Microbiol (2011) 0.92
In vitro activity of echinocandins against non-Candida albicans: is echinocandin antifungal activity the same? Enferm Infecc Microbiol Clin (2011) 0.79
Resistance surveillance program report for selected European nations (2011). Diagn Microbiol Infect Dis (2013) 2.29
Contemporary diversity of β-lactamases among Enterobacteriaceae in the nine U.S. census regions and ceftazidime-avibactam activity tested against isolates producing the most prevalent β-lactamase groups. Antimicrob Agents Chemother (2013) 1.98
Frequency of fks mutations among Candida glabrata isolates from a 10-year global collection of bloodstream infection isolates. Antimicrob Agents Chemother (2013) 1.29
Use of anidulafungin as a surrogate marker to predict susceptibility and resistance to caspofungin among 4,290 clinical isolates of Candida by using CLSI methods and interpretive criteria. J Clin Microbiol (2014) 1.05
Ceftazidime-avibactam activity against multidrug-resistant Pseudomonas aeruginosa isolated in U.S. medical centers in 2012 and 2013. Antimicrob Agents Chemother (2015) 1.05
Antifungal drug resistance among Candida species: mechanisms and clinical impact. Mycoses (2015) 0.99
De Novo Whole-Genome Sequence and Genome Annotation of Lichtheimia ramosa. Genome Announc (2014) 0.97
Relationship between ceftolozane-tazobactam exposure and selection for Pseudomonas aeruginosa resistance in a hollow-fiber infection model. Antimicrob Agents Chemother (2014) 0.88
Phylogeny of the clinically relevant species of the emerging fungus Trichoderma and their antifungal susceptibilities. J Clin Microbiol (2014) 0.87
Efficacy of posaconazole in murine experimental sporotrichosis. Antimicrob Agents Chemother (2012) 0.86
Antimicrobial Activity of High-Proportion Cefepime-Tazobactam (WCK 4282) against a Large Number of Gram-Negative Isolates Collected Worldwide in 2014. Antimicrob Agents Chemother (2017) 0.86
Efficacy of Amphotericin B at Suboptimal Dose Combined with Voriconazole in a Murine Model of Aspergillus fumigatus Infection with Poor In Vivo Response to the Azole. Antimicrob Agents Chemother (2013) 0.81
Assessing micafungin/triazole combinations for the treatment of invasive scedosporiosis due to Scedosporium apiospermum and Scedosporium boydii. J Antimicrob Chemother (2014) 0.80
EUCAST testing of Isavuconazole susceptibility in Aspergillus: comparison of results for Inoculum standardization using Conidium counting versus optical density. Antimicrob Agents Chemother (2014) 0.80
Antimicrobial Susceptibility of Pseudomonas aeruginosa: Results from Four years (2012-2015) of the International Network for Optimal Resistance Monitoring (INFORM) Program in the United States. Antimicrob Agents Chemother (2017) 0.79
Aspergillus-Specific Lateral-Flow Device and Real-Time PCR Testing of Bronchoalveolar Lavage Fluid: a Combination Biomarker Approach for Clinical Diagnosis of Invasive Pulmonary Aspergillosis. J Clin Microbiol (2015) 0.79
Antimicrobial Activities of Ceftazidime-Avibactam and Comparator Agents against Gram-Negative Organisms Isolated from Patients with Urinary Tract Infections in U.S. Medical Centers, 2012 to 2014. Antimicrob Agents Chemother (2016) 0.79
Diagnostic accuracy of the Aspergillus-specific bronchoalveolar lavage lateral-flow assay in haematological malignancy patients. Mycoses (2015) 0.79
Antimicrobial Activity of Ceftazidime-Avibactam When Tested against Gram-negative Bacteria Isolated from Patients Hospitalized with Pneumonia in United States Medical Centers (2011-2015). Antimicrob Agents Chemother (2017) 0.78
Pharmacokinetics-Pharmacodynamics of Tazobactam in Combination with Piperacillin in an In Vitro Infection Model. Antimicrob Agents Chemother (2016) 0.78
In vitro resistance of clinical Fusarium species to amphotericin B and voriconazole using the EUCAST antifungal susceptibility method. Diagn Microbiol Infect Dis (2016) 0.77
Epidemic Emergence in the United States of Escherichia coli Sequence Type 131-H30, 2000-2009. Antimicrob Agents Chemother (2017) 0.77
Experimental therapy with azoles against Candida guilliermondii. Antimicrob Agents Chemother (2014) 0.76
Natural killer cell-mediated damage of clinical isolates of mucormycetes. Mycoses (2015) 0.76
β-Lactamase Characterization of Gram-Negative Pathogens Recovered from Patients Enrolled in the Phase 2 Trials for Ceftazidime-Avibactam: Clinical Efficacies Analyzed against Subsets of Molecularly Characterized Isolates. Antimicrob Agents Chemother (2015) 0.75
Activity of Fusidic Acid Tested against Staphylococci Isolated from Patients in U.S. Medical Centers in 2014. Antimicrob Agents Chemother (2016) 0.75
WCK 5222 (Cefepime-Zidebactam) Antimicrobial Activity against Clinical Isolates of Gram-Negative Bacteria Collected Worldwide in 2015. Antimicrob Agents Chemother (2017) 0.75
Pan-azole-resistant Candida tropicalis carrying homozygous erg11 mutations at position K143R: a new emerging superbug? J Antimicrob Chemother (2017) 0.75
In vitro pharmacodynamics and in vivo efficacy of fluconazole, amphotericin B and caspofungin in a murine infection by Candida lusitaniae. Int J Antimicrob Agents (2013) 0.75
Advances in the management of fungal infections. Mycoses (2015) 0.75
Combination therapy in the treatment of experimental invasive fungal infection by Sarocladium (Acremonium) kiliense. Int J Antimicrob Agents (2014) 0.75
Ceftolozane/tazobactam activity against drug-resistant Enterobacteriaceae and Pseudomonas aeruginosa causing urinary tract and intraabdominal infections in Europe: report from an antimicrobial surveillance programme (2012-15). J Antimicrob Chemother (2017) 0.75
Experimental efficacy of anidulafungin against Aspergillus terreus species complex. Med Mycol (2015) 0.75
Ceftolozane-tazobactam activity against Pseudomonas aeruginosa clinical isolates from US hospitals: Report from an antimicrobial surveillance program (PACTS, 2012-2015). Antimicrob Agents Chemother (2017) 0.75
Antimicrobial Activity of Ceftazidime-Avibactam Tested against Multidrug-Resistant Enterobacteriaceae and Pseudomonas aeruginosa Isolates from U.S. Medical Centers, 2013 to 2016. Antimicrob Agents Chemother (2017) 0.75
Molecular β-lactamase characterization of aerobic Gram-negative pathogens recovered from patients enrolled in the ceftazidime-avibactam phase 3 trials for complicated intra-abdominal infections: Efficacies analyzed against susceptible and resistant subsets. Antimicrob Agents Chemother (2017) 0.75
Antimicrobial Activity of Aztreonam-Avibactam and Comparator Agents Tested against Contemporary (2016) Clinical Enterobacteriaceae Isolates. Antimicrob Agents Chemother (2017) 0.75